The Arrival of Precision Gene Therapy with Base and Prime Editing
Discover how the development of base and prime editing has surpassed the limitations of previous CRISPR therapeutics.
What is CRISPR Gene Editing Technology?
CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats) is the foundational gene editing approach that uses the Cas9 enzyme to make precise cuts to DNA. The body's natural repair process will then make the desired change to DNA at the cut site permanently.
The development of the CRISPR/Cas9 system has revolutionized biotechnology due to its simplicity, speed, and affordability compared to previous gene editing methods. In human health, CRISPR is being intensively researched to develop gene therapies for complex diseases like Sickle Cell Anemia, Cystic Fibrosis, and various cancers by correcting or disabling pathogenic genes.
Limitations of Standard CRISPR Therapies
As promising as CRISPR technology has been so far, there are still some limitations to standard CRISPR therapies. Its main limitation is its reliance on inducing a DNA double-strand break (DSB) to initiate the editing process.
This DSB is repaired by the cell’s natural, error-prone repair mechanisms, often resulting in small, random insertions or deletions. Although this is ideal for gene knockout, it lacks the precision required for correcting single-letter mutations without unpredictable byproducts.
The Next Generation
Early CRISPR systems were powerful, but their reliance on cutting both strands of DNA often led to unwanted, imprecise changes. To overcome this critical challenge, Dr. David Liu and his team developed two groundbreaking, "cut-free" technologies: base editing and prime editing.
Base Editing
Base editing seeks to overcome the limitations of standard CRISPR therapeutics by using a modified Cas9 enzyme that cuts only one strand of the DNA, or even none at all. This avoids the genotoxic risks associated with DSB.
Base editors are highly efficient at making precise, single-nucleotide transitions (such as C to T or A to G) without creating indels. However, their scope is limited to only four of the twelve possible base-pair swaps. To accomplish all 12 possible base-pair swaps, prime editing was developed.
Prime Editing
Prime editors offer the greatest versatility of the CRISPR solutions listed, functioning as a search and replace tool. They can perform all twelve base-pair swaps, as well as targeted small insertions and deletions, all without relying on a DSB or a separate donor DNA template.
Prime editing is not without its challenges though, as the larger size of the editor complex can provide delivery challenges.
Current Clinical Trials
Although both base and prime editing are relatively young therapies, with base editing being invented 9 years ago and prime 6 years ago, several therapeutic candidates utilizing these precise technologies have rapidly progressed into clinical trials.
One prominent example is VERVE-102 (Verve Therapeutics, recently acquired by Eli Lilly), a CRISPR base editing product currently undergoing a Heart-2 Phase 1b trial. This in-vivo therapy is delivered via intravenous (IV) infusion and targets the PCSK9 gene in the liver, a key regulator of low-density lipoprotein cholesterol.
Early Phase 1 results have been encouraging, showing no clinically significant laboratory abnormalities or treatment-related serious adverse events, with the company planning to advance to Phase 2 upon final evaluation of the dose-escalation data.
Another notable treatment comes from Beam Therapeutics, who are in clinical trials with BEAM-101, which aims to support differentiated profiles in sickle cell disease. BEAM-101 is also a base editing treatment. It is currently in the BEACON Phase 1/2 trial, with the latest press release from November 3, 2025, announcing the upcoming presentation of updated trial data at the American Society of Hematology (ASH) Annual Meeting in December 2025.
Potential Challenges
Base and prime editing tackle some of the challenges of standard CRISPR therapies, but they come with their own set of challenges. Both struggle with delivery efficiency and size. Prime editors, in particular, are physically large. This size can complicate packaging into common viral vectors like AAVs, which are critical for delivering therapies into the body.
Base editing is currently limited in scope, only being able to facilitate six of the twelve possible single-base conversions. Unfortunately, this means many disease-causing point mutations cannot be corrected using base editing alone. This challenge can partially be credited for the development of prime editing, which can facilitate all twelve conversions.
Finally, a major challenge for base editing is bystander editing. Although base editing is regarded as safer than traditional CRISPR/Cas9, base editors can still cause unintended modifications. Bystander editing occurs when a base editor makes an unwanted change to a neighboring base within the intended editing window.
Future Outlook and Potential Applications
The future of base and prime editing is incredibly promising. Prime editing has a particularly positive outlook due to its versatility. Computational models suggest it could theoretically correct up to 89% of known pathogenic human genetic variants, including single-nucleotide substitutions, small insertions, and deletions (indels). This level of precision is ideal for tackling complex monogenic diseases like cystic fibrosis and muscular dystrophy.
Base and prime editing technologies are well-suited for editing large genes that exceed the cargo capacity of traditional viral vectors, and they offer a definitive way to treat autosomal dominant diseases by precisely silencing or correcting the defective gene copy.
Additionally, the ability to perform multiple, stacked edits simultaneously, called multiplex editing, is being developed to treat complex diseases involving multiple gene mutations at once, with greater safety than traditional CRISPR.
Beyond rare genetic disorders, the applications of base and prime editing are rapidly expanding into broader therapeutic and industrial areas. These tools are being developed for use in cancer immunotherapy, specifically by editing T-cells ex vivo to enhance their tumor-fighting capability. They also hold promise in infectious disease management by targeting viral DNA directly to generate broad-spectrum immunity.
Share article
About HPNE
As the industry needs grow, High Purity New England, Inc. continues to supply the biopharmaceutical industry with a range of innovative products, from drug discovery and development to fill-finish, including their flagship product, custom single-use assemblies, as well as pumps, sensors, bioreactor systems, storage and handling solutions and other single-use solutions. Along with their own manufactured products for the global market, they are also a distributor for more than 18 brands in North America.
